Journal of diabetes and its complications最新文献

{"title":"Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy","authors":"Jocelynn King ,&nbsp;Elizabeth Buschur ,&nbsp;Rachel Garcetti ,&nbsp;Laura Pyle ,&nbsp;Casey Sakamoto ,&nbsp;Janet Snell-Bergeon ,&nbsp;Emily Nease ,&nbsp;Anna Bartholomew ,&nbsp;Kathleen Dungan ,&nbsp;Sarit Polsky","doi":"10.1016/j.jdiacomp.2025.109000","DOIUrl":"10.1016/j.jdiacomp.2025.109000","url":null,"abstract":"<div><h3>Aims</h3><div>We compared changes in insulin pump settings and insulin distribution throughout pregnancy and early postpartum for participants with type 1 diabetes using sensor-augmented pump therapy (SAPT) or hybrid closed-loop (HCL) therapy without a pregnancy-specific glucose target.</div></div><div><h3>Methods</h3><div>In this investigator-initiated trial 23 participants were randomized at 14–18 weeks gestation to HCL therapy or SAPT until 4–6 weeks postpartum. We compared the changes to insulin pump settings and insulin delivery between groups using mixed-effects models.</div></div><div><h3>Results</h3><div>There were no significant differences in total daily insulin dose between HCL and SAPT groups from preconception through 4–6 weeks postpartum. However, the proportion of total insulin coming from bolus insulin was higher for the HCL group in month 9 (70.9 % HCL vs 57.9 % SAPT, p = 0.014). The HCL group had a lower total daily basal dose compared to SAPT in months 9 and 10 (p &lt; 0.05 for both) and a higher total daily bolus dose at month 10 compared to the SAPT group (55.2 units/day vs 37.1 units/day, p = 0.025). The number of changes to pump settings did not differ between groups. Active insulin time was significantly shorter in the HCL group at almost all time points through month 9 of pregnancy and early postpartum. Carbohydrate-to-insulin ratios were stronger for breakfast (p = 0.020) and lunch (p = 0.005) over gestation in the HCL group.</div></div><div><h3>Conclusion</h3><div>More bolus insulin and less basal insulin were used by the HCL group compared to the SAPT group, at least in part due to pump settings that contribute to more bolus insulin delivery.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109000"},"PeriodicalIF":2.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the therapeutic effects of pregabalin, gabapentin, and duloxetine in diabetic peripheral neuropathy: A retrospective study","authors":"Jiyong Ahn ,&nbsp;Reza Shahriarirad ,&nbsp;Kyeongeon Kwon ,&nbsp;Lorena Bejarano-Pineda ,&nbsp;Gregory Waryasz ,&nbsp;Soheil Ashkani-Esfahani","doi":"10.1016/j.jdiacomp.2025.109001","DOIUrl":"10.1016/j.jdiacomp.2025.109001","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to compare the effects of pregabalin, gabapentin, and duloxetine on diabetic peripheral neuropathy (DPN) to guide tailored treatment.</div></div><div><h3>Materials and methods</h3><div>In this retrospective study, 180 patients with type 2 diabetes and DPN were matched 1:1:1 across three groups based on HbA1c and age, resulting in 60 patients per group. Clinical data were collected, and the painDETECT score was used to evaluate treatment response over six weeks.</div></div><div><h3>Results</h3><div>After six weeks, the gabapentin group had significantly higher pain scores than the pregabalin (P = 0.002) and duloxetine groups (P &lt; 0.001). The pregabalin group's scores were higher than the duloxetine group's, but not significantly (P = 0.62). Side effects were more frequent with duloxetine (23.3 %) compared to gabapentin (1.7 %) and pregabalin (6.7 %) (P = 0.001). Among those with over 50 % improvement, mean HbA1c levels were 9.42 for gabapentin, 10.43 for pregabalin, and 7.72 for duloxetine. Duloxetine significantly lowered HbA1c compared to gabapentin (P = 0.001) and pregabalin (P = 0.001), with no significant difference between gabapentin and pregabalin (P = 0.45).</div></div><div><h3>Conclusion</h3><div>Duloxetine and pregabalin effectively treat DPN. Gabapentin and pregabalin are suitable for patients with HbA1c over 8.7, while duloxetine is better for those with well-controlled HbA1c. Treatment should consider side effects, adherence, costs, and response time.</div></div><div><h3>Level of the evidence</h3><div>Level III retrospective cohort study.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109001"},"PeriodicalIF":2.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of non-surgical treatment in diabetes-associated periodontitis on immune/inflammatory and oxidative stress biomarkers: A pilot study","authors":"Steffany Bernardo Oliveira ,&nbsp;Ana Luíza Pereira Assunção Silveira ,&nbsp;Yeon Jung Kim ,&nbsp;Jônatas Bussador do Amaral ,&nbsp;André Luis Lacerda Bachi ,&nbsp;Margareth Afonso Torres ,&nbsp;Karen Melissa Gonçalves Oliveira ,&nbsp;Daniela Alves de Abreu ,&nbsp;Leonardo Diniz Resende ,&nbsp;Débora Pallos ,&nbsp;Carolina Nunes França","doi":"10.1016/j.jdiacomp.2025.108999","DOIUrl":"10.1016/j.jdiacomp.2025.108999","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of non-surgical periodontal treatment on the levels of cytokines, sIgA, antimicrobial peptides, oxidative and antioxidative agents in comparison between patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A case-control study that included patients (n = 45) with periodontitis who have or do not have diabetes. Cytokine concentrations in crevicular gingival fluid (GCF) and saliva were determined using LUMINEX and ELISA assays, respectively. Salivary levels of lysozyme, cathelicidin (LL-37), total antioxidant capacity (TAC) and total peroxide were determined colorimetrically before (T0) and one month after completion of periodontitis treatment (T1).</div></div><div><h3>Results</h3><div>There were no significant differences in the concentrations of cytokines in GCF between the groups and T0 and T1. Salivary concentrations of lysozyme and IL-10 were significantly reduced in T1 compared to T0 in the diabetes group (p = 0.0260 and p = 0.0034, respectively), whilst TNF-α concentration was higher in T1 (p = 0.0443). The salivary concentrations of TNF-α observed in the non-diabetes group at T1 decreased at T0 (p = 0.0313). The salivary concentration of TNF-α was increased in the diabetes group compared to the non-diabetes group at T1 (p = 0.0008).</div></div><div><h3>Conclusions</h3><div>An improvement in salivary inflammatory status was observed in the group without diabetes, which was not found in the group with diabetes after non-surgical periodontal treatment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108999"},"PeriodicalIF":2.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of the stress hyperglycemia ratio for all-cause mortality in stroke patients with diabetes or prediabetes","authors":"Meng Jin ,&nbsp;Ziyi Bao ,&nbsp;Xiaqing Hong ,&nbsp;Songbin He ,&nbsp;Feng Gao","doi":"10.1016/j.jdiacomp.2025.108979","DOIUrl":"10.1016/j.jdiacomp.2025.108979","url":null,"abstract":"<div><h3>Background</h3><div>The stress hyperglycemia ratio (SHR), originally proposed in 2015 by Robert et al., is more significantly relevant and predictive of critical illness than absolute hyperglycemia. Several studies have validated the association between stress hyperglycemia ratio and cerebrovascular disease. However, the value of stress hyperglycemia ratio for severe stroke patients admitted to the ICU remains uncertain. The aim of this study was to investigate the relationship between stress hyperglycemia ratio and clinical short- and long-term prognosis of critically ill patients with acute ischemic stroke (AIS).</div></div><div><h3>Methods</h3><div>Clinical data from 893 critically ill patients with ischemic stroke (IS) were extracted from the Medical Information Marketplace for Intensive Care (MIMIC-IV) database and 793 critically ill IS patients with 1 year of follow-up. The SHR is expressed by the formula: SHR = [(admission glucose (mg/dl)) / (28.7 × HbA1c (%) − 46.7)]. The study population was categorized into quartiles based on SHR level. Outcomes included ICU mortality, hospital mortality, and 1-year mortality. Cox proportional risk regression analysis and restricted cubic spline curves were used to elucidate the association between SHR and clinical prognosis in critically ill patients with AIS.</div></div><div><h3>Results</h3><div>There were 69 ICU deaths and 100 in-hospital deaths in cohort 1, and 229 patients experienced all-cause mortality during the 1-year follow-up in cohort 2. Multivariate Cox proportional risk analysis showed that elevated SHR was significantly associated with an increased risk of hospital and 1-year all-cause mortality. After adjusting for confounders, patients with elevated SHR were significantly associated with hospital mortality (adjusted risk ratio, 1.870; 95 % confidence interval, 1.180–2.962; <em>P</em> = 0.008) and 1-year mortality (adjusted risk ratio, 2.325; 95 % confidence, 1.729–3.127; <em>P</em> &lt; 0.001). Restricted cubic spline bars showed that a progressively increasing risk of all-cause mortality was associated with an elevated SHR.</div></div><div><h3>Conclusion</h3><div>Stress hyperglycemia ratios were significantly associated with in-hospital and 1-year all-cause mortality in critically ill IS patients. Moreover, we found that non-diabetic and prediabetic patients showed an increased risk of all-cause mortality. It is suggested that SHR may be useful in identifying ischemic stroke patients at high risk of all-cause mortality and providing personalized interventions as early as possible.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108979"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143632102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating social determinants of health into global approaches to early-onset type 2 diabetes","authors":"J. Eleanor Seo ,&nbsp;Manfredi Rizzo ,&nbsp;Tiffany M. Powell-Wiley","doi":"10.1016/j.jdiacomp.2025.108982","DOIUrl":"10.1016/j.jdiacomp.2025.108982","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108982"},"PeriodicalIF":2.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and safety of pioglitazone and SGLT2 inhibitors in treating Asian patients in MASLD associated with type 2 diabetes: A meta-analysis","authors":"Lingyan Liu ,&nbsp;Yongkun Deng ,&nbsp;Lijuan Yang ,&nbsp;Miaojiao Wang ,&nbsp;Yong Lai","doi":"10.1016/j.jdiacomp.2025.108998","DOIUrl":"10.1016/j.jdiacomp.2025.108998","url":null,"abstract":"<div><h3>Objective</h3><div>To comprehensively evaluate the therapeutic efficacy of pioglitazone and SGLT2 inhibitors (SGLT2i) in patients with MASLD and Type 2 Diabetes(T2DM).</div></div><div><h3>Methods</h3><div>Electronic databases, including Web of Science, PubMed, the Cochrane Library, China National Knowledge Internet (CNKI), Wan-Fang Digital Database, and China Science and Technology Journal Database (VIP) were searched from inception to December 2024. Two reviewers independently assessed study eligibility, performed continuous data extraction， and independently evaluated bias risks. Liver ultrasonography, computed tomography (CT), and biochemical indices were utilized to determine the impact of treatment in both groups. Improvement in liver biomarkers and fibrosis as primary outcome indicators; Improvement in body composition, metabolic parameters, glucose parameters, and incidence of adverse effects as a secondary outcome indicator. For continuous variables, mean and standard deviation (SD) were extracted. RevMan 5.4 software was used to systematically analyze the literature, including heterogeneity testing, odds ratios (OR) calculation, and 95 % confidence intervals (CI) for each influencing factor.</div></div><div><h3>Results</h3><div>Nine randomly controlled trials with 755 Asian participants were included. Our research showed that SGLT2i was more effective than pioglitazone in improving fibrosis-4 score (SMD 0.41 [95%CI 0.18,0.64] <em>p</em> = 0.005), visceral fat area (SMD 0.34 [95%CI 0.14,0.54] <em>p</em> = 0.0007), BMI (SMD 0.29 [95%CI 0.03,0.56] <em>p</em> = 0.03), and low-density lipoprotein levels (SMD 0.21 [95%CI 0.04,0.38] <em>p</em> = 0.01). In contrast, no statistically significant differences were observed in other outcomes.</div></div><div><h3>Conclusions</h3><div>Our study demonstrated that in patients with MASLD and T2DM, SGLT2i was more effective overall in improving liver fibrosis, blood lipids, liver fat, and body composition in the short term. These findings establish a theoretical basis for safe and rational drug use in clinical practice. Additionally, they may contribute to new insights into the pathogenesis of MASLD and type 2 diabetes and drug discovery and development efforts.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108998"},"PeriodicalIF":2.9,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"sCD14 as a biomarker for the progression of kidney disease among patients with diabetes","authors":"Oscar Zaragoza-García ,&nbsp;Olivia Briceño ,&nbsp;José Rafael Villafan-Bernal ,&nbsp;Héctor Ugo Rojas-Delgado ,&nbsp;Ilse Adriana Gutiérrez-Pérez ,&nbsp;Cristina Morales-Martínez ,&nbsp;Roma Rubí Rodriguez-Reyes ,&nbsp;Iris Paola Guzmán-Guzmán","doi":"10.1016/j.jdiacomp.2025.108980","DOIUrl":"10.1016/j.jdiacomp.2025.108980","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the association of soluble CD14 (sCD14) with diabetic kidney disease (DKD) and its prediction performance for kidney function staging.</div></div><div><h3>Methods</h3><div>A cross-sectional study of 80 type 2 diabetes (T2D) patients was conducted. Each participant was screened for DKD, and the diagnostic criterion for DKD was a glomerular filtration rate (eGFR) &lt;60 mL/min/1.73m². Serum sCD14 was measured by ELISA technique. Logistic regression models and receiver operating characteristics (ROC) curves were used to assess the association of sCD14 with DKD and its predictive value for disease staging.</div></div><div><h3>Results</h3><div>sCD14 was higher in DKD patients than in T2D patients without kidney disease (<em>p</em> &lt; 0.001). sCD14 was progressively higher in DKD patients according to the kidney function stage (<em>p</em> &lt; 0.001). Also, sCD14 was higher in DKD patients in hemodialysis than those who did not receive renal replacement therapy (<em>p</em> &lt; 0.001). In DKD patients, sCD14 was positively correlated with creatinine (<em>r</em> = 0.282, <em>p</em> = 0.042) and negatively correlated with eGFR (<em>r</em> = −0.365, <em>p</em> = 0.007). The levels of sCD14 were predictive of G3 (AUC = 0.822), G4 (AUC = 0.876), and G5 (AUC = 0.924) stages of kidney function. In a multivariate logistic regression model adjusted for age, sex, and diabetes duration, sCD14 ≥ 1720 ng/mL were associated with G3 stage (OR = 8.92, <em>p</em> = 0.023), G4 (OR = 7.92, <em>p</em> = 0.011) and G5 stage (OR = 18.47, <em>p</em> = 0.017) in DKD patients.</div></div><div><h3>Conclusion</h3><div>Circulating levels of sCD14 are associated with DKD and perform well for kidney function staging. Thus, it is a good candidate for assessing the risk of kidney disease progression.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108980"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143508483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of automated insulin delivery (AID) systems on quality of life (QoL): Validation of the AID-QoL questionnaire","authors":"Giuseppe Papa ,&nbsp;Rossella Cannarella ,&nbsp;Concetta Finocchiaro ,&nbsp;Massimiliano Anzaldi ,&nbsp;Gianfranco Gruttadauria ,&nbsp;Donatella Lo Presti ,&nbsp;Rosita A. Condorelli ,&nbsp;Sandro La Vignera ,&nbsp;Aldo E. Calogero","doi":"10.1016/j.jdiacomp.2025.108984","DOIUrl":"10.1016/j.jdiacomp.2025.108984","url":null,"abstract":"<div><h3>Background and aim</h3><div>Evidence supports the efficacy of automated insulin delivery (AID) systems in improving glycometabolic outcomes. However, limited data are available on their impact on quality of life (QoL). This study aimed to develop and validate a questionnaire to assess QoL in subjects with type 1 diabetes mellitus (T1DM) using AID system (AID-QoL).</div></div><div><h3>Patients and methods</h3><div>A questionnaire was developed and validated following a standardized procedure and administered to 219 subjects with T1DM who were using AID systems for insulin therapy.</div></div><div><h3>Results</h3><div>Analysis of inter-expert agreement for internal consistency showed a Cronbach's alpha coefficient of 0.720, suggesting an acceptable level of consistency across the 29 items of the AID-QoL. The infraclass correlation coefficient for retest agreement was 0.745, demonstrating “substantial” reliability. Administration of the questionnaire to the 219 subjects with T1DM showed that AID systems contributed to high satisfaction with glycometabolic management, a slightly lower satisfaction with the technical aspects of the AID systems, a positive impact on psychological and social well-being, and a high level of confidence in the technology.</div></div><div><h3>Conclusion</h3><div>The AID-QOL questionnaire is a newly validated, reliable, easy-to-use tool for measuring QoL and satisfaction in subjects with T1DM who are receiving insulin treatment via AID systems.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108984"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-directed medical therapies (GDMTs) for chronic kidney disease with type 2 diabetes (CKD + T2D): Translation of lessons learned from the management of heart failure","authors":"Jonathan Rollins ,&nbsp;Alison L. Hong ,&nbsp;Bridgette Schroader ,&nbsp;Sheldon X. Kong ,&nbsp;Barb Lennert ,&nbsp;Jennifer Cameron ,&nbsp;Rakesh Singh ,&nbsp;Yuxian Du ,&nbsp;Todd Williamson","doi":"10.1016/j.jdiacomp.2025.108985","DOIUrl":"10.1016/j.jdiacomp.2025.108985","url":null,"abstract":"<div><div>Although guideline-directed medical therapy (GDMT) is an evidence-based, proven approach to manage chronic kidney disease and type 2 diabetes (CKD + T2DM), adherence is low and multifactorial. Opportunities exist to improve care delivery, thus delaying disease progression, avoiding unnecessary costs, and potentially improving quality of life for patients both diagnosed and yet to be diagnosed.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108985"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00043-1","DOIUrl":"10.1016/S1056-8727(25)00043-1","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 3","pages":"Article 108990"},"PeriodicalIF":2.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143528872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}